Jon Faiz Kayyem
CIK 1366268 · SVP, Research & Development · last filed 2026-06-04
Jon Faiz Kayyem is a SVP, Research & Development who has filed 100 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for INBX, was dated Jun 4, 2026. Across all open-market trades the lifetime net is +$729.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $44.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$44.05M
4
100
$729.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INBX | Director | 419,360 | $92.20 | $38.66M | $1.45M | 18 | 2026-06-04 |
| BDSX | Director | 357,537 | $15.06 | $5.38M | $200.0K | 13 | 2026-01-06 |
| Inhibrx, Inc. (INBXV) Delisted | Director | 0 | — | — | $0 | 1 | 2024-05-30 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | SVP, Research & Development | 286,306 | $24.04 | $6.88M | -$924.2K | 62 | 2018-02-06 |
Recent Filings
100 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | INBX | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | BDSX | Grant (A) | — | $0 | EDGAR |
| 2025-05-29 | INBX | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | BDSX | Grant (A) | — | $0 | EDGAR |
| 2025-03-28 | INBX | Gift (G) | −90,000 | $0 | EDGAR |
| 2024-12-17 | INBX | Gift (G) | — | $0 | EDGAR |
| 2024-12-06 | INBX | Gift (G) | −52,000 | $0 | EDGAR |
| 2024-11-22 | INBX | Buy (P) | +107,186 | $1.52M | EDGAR |
| 2024-06-24 | INBX | Gift (G) | −69,050 | $0 | EDGAR |
| 2024-06-07 | INBX | Buy (P) | +57,549 | $997.0K | EDGAR |